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Abstract 
 
Lambert-Eaton Myasthenic Syndrome (LEMS) is a debilitating autoimmune disease 
where the neuromuscular junction (NMJ) does not function normally. A patient with 
LEMS has damaged voltage-gated calcium channels (VGCC), which in return does 
not allow their NMJ to release an adequate amount of acetylcholine for muscle 
contraction. A novel treatment for LEMS is administering 3,4-Diaminopyridine (3,4-
DAP), because the drug blocks presynaptic potassium channels and broadens 
presynaptic action potentials. Since presynaptic action potentials are broadened, 
more influx of calcium through VGCC occurs, and additional acetylcholine is 
released, reducing the muscle weakness associated with LEMS. To further LEMS 
research, we used a frog model (gastrocnemius muscle and the sciatic nerve). The 
frog muscle and nerve were soaked in different calcium concentrations to simulate 
LEMS. After we collected control data, we treated the muscle-nerve preparation 
with 3,4-DAP and investigated the effects 3,4-DAP has on muscle excitability and 
nerve excitability. We predicted that muscle twitch (force) generated by nerve 
stimulation would be enhanced by 3,4-DAP treatment but that direct muscle 
stimulation would be unaffected. We find that the research supports our original 
hypothesis. 
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3,4-Diaminopyridine as a Treatment for Lambert-Eaton Myasthenic Syndrome 
(LEMS) 
 
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disease that is 
caused by defects in the neuromuscular junction (NMJ). In addition to being an 
autoimmune disease, LEMS is also characterized as a paraneoplastic disorder in 
approximately half of the patient’s affected (Gilhus 1). Individuals with an 
autoimmune disease have a defective immune system caused by the body attacking 
its’ own tissues. A paraneoplastic disorder is a condition that is caused by the 
patient’s immune system responding to a cancerous tumor in the body. 
Approximately 50% of LEMS patients also have small cell lung carcinoma (SCLC), 
which is what gives LEMS the paraneoplastic disorder classification (Gilhus 3). The 
remaining 50% of patient’s diagnosed with LEMS have an idiopathic form; 
researchers cannot definitively say what caused the autoimmune disorder (Tarr et 
al. 458). 
 
Lambert-Eaton Myasthenic Syndrome (LEMS) can cause numerous side effects such 
as dry mouth and constipation, but the most common and serious side effect is 
muscle weakness. The muscle weakness is debilitating because every day tasks such 
as walking and lifting objects becomes difficult. Nearly 80% of patient’s with LEMS 
experience muscle weakness in both their arms and legs (Gilhus 2). As previously 
mentioned, LEMS is an autoimmune disorder; in this disorder, antibodies attack 
voltage-gated calcium channels (VGCC), specifically the P/Q-type. The attack on 
VGCC causes a reduction in the number of calcium channels and a reduction in the 
calcium influx. Since calcium influx is the trigger for neurotransmitter release, 
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damage to the VGCC causes a reduction in the amount of acetylcholine, the 
neurotransmitter needed to initiate muscle contraction. The insufficient amount of 
acetylcholine is what causes a weaker muscle contraction in a person with LEMS 
compared to an individual without LEMS.  
 
Since LEMS affects every day tasks, receiving the appropriate treatment with the 
least amount of side effects is crucial for a patient’s quality of life. Patient’s who have 
SCLC receive cancer treatment first. Since the patient’s have a paraneoplastic 
disorder (LEMS), the successful removal of the cancer will alleviate symptoms (Tarr 
et al. 459). However, the disappearance of symptoms with cancer treatments is only 
possible if the cancer is what caused LEMS. For the patients that have the idiopathic 
form of LEMS or their symptoms just do not go away there are other drug therapy 
options available. The standard treatment for LEMS is a drug called 3,4-
Diaminopyridine (3,4-DAP). The drug blocks presynaptic potassium channels and 
broadens presynaptic action potentials. Since presynaptic action potentials are 
broadened, more influx of calcium through the remaining VGCC occurs, and 
additional acetylcholine is released, reducing the muscle weakness associated with 
LEMS. 
 
The research I performed this past school year focused on 3,4-DAP as a treatment 
for LEMS. My research mentor Dr. Robert Poage and I designed the experiment and 
set up the research parameters in the Fall 2018 semester. The data collection and 
analysis took place in the Spring 2019 semester with the help of the BIO 4610 
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(Animal Physiology) class. Dr. Poage and I were interested in whether muscle twitch 
(force) generated by nerve stimulation and muscle twitch (force) generated by 
direct muscle stimulation would be enhanced by 3,4-DAP treatment. We predicted 
that muscle twitch (force) generated by nerve stimulation would be enhanced by 
DAP treatment but that direct muscle stimulation would be unaffected. 
 
The model animal used for our research was an adult leopard frog (Rana pipiens), 
because frogs are the standard animal model when performing experiments with 
the neuromuscular junction (NMJ); frogs are the animal model for this type of 
research because their NMJ is well understood and similar to humans. Additionally, 
the BIO 4610 class generally does a similar lab to the one we performed, so the frogs 
were more readily available than other options. Finally, frogs are easier to care for 
in a laboratory setting compared to other animals like mice. The frogs were cared 
for by Dr. Poage and other lab technicians at the University of North Carolina at 
Pembroke. Our lab protocol was approved by UNC-Pembroke’s Institutional Animal 
Care and Use Committee; the purpose of the committee reviewing our research plan 
was to ensure that the frogs were treated humanely and in accordance with federal 
research guidelines.   
 
Methods 
Adult leopard frogs (Rana pipiens) were decapitated and pithed after anesthesia in 
0.1% tricaine methane sulfonate solution. The gastrocnemius muscle and sciatic 
nerve preparation was removed bilaterally and bathed in normal frog Ringer’s 
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solution (NFR) (in mM: 111 NaCl, 2 KCl, 1.0 mM TrisCl, 1.8 CaCl2,  pH 7.3-7.5). After 
1-2 hours sitting unstimulated at room temperature, the preparation was affixed 
with pins to a wax or cork substrate.  The calcaneal tendon was tied off with surgical 
suture thread and cut from its distal attachment.  The other end of the thread was 
attached to a force transducer (FT-104, iWorx) which was mounted horizontally on 
a ring stand above the muscle preparation. Tension was applied to the thread by 
raising the force transducer to 10-30 cm above the muscle preparation.  The output 
of the force transducer was routed into an analog-digital converter (IWX-214, 
iWorx) which was controlled by Labscribe3 software (iWorx) through a PC-
interface.  The integrated stimulator of the IWX-214 unit was directed to a sleeve-
type electrode (BNC-SE) attached to the sciatic nerve of the preparation for 
stimulation of sciatic nerve motor axons.  Finally, a separate set of needle electrodes 
(BNC-N2) were inserted, one into either end of the gastrocnemius, for direct 
electrical stimulation of the muscle cells. The students stimulated either the muscle 
or nerve at 0.0,  0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, and 5.0 volts. 
The output (contractile force) was measured in grams. 
Results 
The data was collected by the Animal Physiology students during two separate two 
hour lab sessions, January 31, 2019 and February 7, 2019. The data collected in 
January was strictly control data;  the gastrocnemius muscle and sciatic nerve was 
soaked only in normal frog Ringer’s solution (NFR) (in mM: 111 NaCl, 2 KCl, 1.0 mM 
TrisCl, 1.8 CaCl2,  pH 7.3-7.5). The data collected in February consisted of more 
control data as well as the muscle and nerve preparation treated with 3,4-
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Diaminopyradine. Both sets of data were collected by six groups of students; each 
group had 2-3 students, and the groups were put together at random. The names of 
the groups were: Drosophila, Leech, Rana, Mus, Rattus, and Squid. In January, there 
were two different ringer’s solutions used. Each solution had three groups of 
students assigned to it at random; the solution that best simuluated LEMS was the 
0.3 millimolar calcium solution instead of the 0.5 millimolar calcium solution. The 
data collected in February was collected by six groups; three of the groups used the 
same control solution (0.3 millimolar calcium), and the other three groups had the 
control solution and 3,4-DAP. 
 
As previously mentioned, the students stimulated the muscle or the nerve at 
different increments between 0.0-5.0 volts. When sufficiently stimulated, the muscle 
contracted and a contractile force (grams) was recorded. Each group generated a 
full set of data, but for comparison purposes, we averaged all of the 0.3 millimolar 
calcium control data together (6 groups, over the 2 lab sessions)  and the set of data 
that consisted of 0.3 millimolar calcium solution and 3,4-DAP (3 groups, over 1 lab 
session) . Figure 1A (below)  shows the stimulus and averages for when the students 
stimulated nerve directly.  
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Figure 1A. Left column, voltage at which nerve was stimulated. Middle column, 
average force (g.) generated when muscle contracted in control (0.3 mM Calcium, 
blue line and triangles in Figure 1B). Right column, average force (grams) generated 
when muscle contracted in the DAP experiments (orange line and squares in figure 
1B). 
 
 
Figure 1B.  Effect of DAP on contractile force by nerve stimulation. Nerve 
stimulation control data (0.3 millimolar Calcium solution: 1/31/2019 & 2/07/2019, 
blue line/triangles) versus DAP data (0.3 millimolar Calcium solution plus 1 mM 3,4-
Diaminopyridine 2/07/2019, orange line/squares). The data on this graph 
corresponds with Figure 1A.  
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The control data for nerve stimulation (middle column in Figure 1A) has a peak 
contractile force of 10.524 grams at a stimulus of 0.8 volts. The data for the 3,4-DAP 
groups has a peak contractile force of 29.678 grams at 0.2 volts. 3,4-DAP allowed a 
significant increase (182.0% increase) in contractile force and also allowed the 
muscle to hit its’ peak at a much lower stimulus (0.2 volts versus 0.8 volts). The 
higher contractile force reflects a stronger muscle contraction, meaning patients 
with LEMS should be able to complete day to day tasks easier. 
 
 
Figure 2A. Data from Figure 2B. Left column, voltage at which muscle was 
stimulated. Middle column, average force (grams) generated by muscle contraction 
in control (0.3 mM 2B Calcium, blue line in Figure 2B). Right column, average force 
(grams) generated by muscle contraction in the DAP experiments (orange line in 
figure 2B). 
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Figure 2B. Effect of 3,4-DAP on contractile force by muscle stimulation. Comparison 
between two experimental conditions: muscle control data (1/31/2019 & 
2/07/2019, blue line/triangle) and the 3,4-DAP data (orange line/squares).  
 
The control data (middle column in Figure 2A) has a peak contractile force of 35.271 
grams, and the 3,4-DAP data has a peak contractile force of 33.673 grams. The 
control data, where the frog tissue was not treated with 3,4-DAP actually had  a 
slightly higher peak contractile force. The peak contractile force decreased by 4.5%. 
 
Conclusion 
3,4-DAP had a significant effect on how strongly muscle contracts when the nerve is 
stimulated, but the medication had little or no effect on muscle contraction when the 
muscle was stimulated directly. Our research supports our original hypothesis 
because muscle twitch (force) generated by nerve stimulation was enhanced by 3,4-
DAP treatment but direct muscle stimulation did not see an enhancement of greater 
than 10%. 
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If 3,4-DAP had significantly affected peak muscle contraction with direct muscle 
stimulation then that would be an area for concern. It would be an area for concern 
because scientists only want 3,4-DAP to increase neurotransmitter release and not 
additionally effect the muscle directly. If the results had turned out differently, we 
would have looked at how 3,4-DAP affects cardiac muscle and smooth muscle. 
 
For future directions, we would like to repeat the experiment but incorporate 
another drug called GV-58, which is a calcium channel agonist. GV-58 and 3,4-DAP 
work synergistically together to completely reverse the muscle weakness associated 
with LEMS (Tarr et al. 461). The two drugs together is a safer option that would be 
available to more patient’s. 3,4-DAP is not an available option for some patient’s 
because once the drug gets to a high dose (generally > 80 mg per day), there are too 
many side effects. The drugs work synergistically together because 3,4-DAP increase 
the amount of calcium channels open and GV-58 allows each the channel to stay 
open longer; the combination of these two factors allows a greater calcium influx, 
specifically at the LEMS-damaged structure, the NMJ (Tarr et al. 460). 
In conclusion, 3,4-DAP enhances muscle contractile force by nerve stimulation but 
not by muscle stimulation. The research we performed supported our original 
hypothesis. 3,4-DAP is able to enhance muscle contractile force, because the drug 
blocks presynaptic potassium channels and broadens presynaptic action potentials. 
Since presynaptic action potentials are broadened, more influx of calcium through 
VGCCs occurs, and additional acetylcholine is released, reducing the muscle 
weakness associated with LEMS. 
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